Clinical trials: Dose Finding Study
Advanced Solid Tumors
A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors
To assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile and efficacy of JPI-547 in patients with advanced solid tumor.
- Trial name
- NCT04335604
- Testing
- JPI-547
- Where
- 2 sites in South Korea
- Volunteers
- 62 people
- Sponsor
- Onconic Therapeutics Inc.
Glabellar Frown Lines
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
The purpose of this study is to find an optimal dose to determine the safety and tolerability of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular injection in subjects with glabellar lines…
- Trial name
- NCT01485601
- Testing
- MT10109
- Where
- Australia
- Volunteers
- 121 people
- Sponsor
- Medy-Tox
Tibia Plateau Fractures
Safety and Efficacy of I 0401 in the Treatment of Tibial Plateau Fractures Requiring Grafting
For certain tibial plateau fractures the bone is compressed due to the force acting on the tibia during the accident. The void provoked by the compression of the bone is filled with an appropriate filling material and the…
- Trial name
- NCT00409799
- Testing
- I-0401 (a new bone graft substitute)
- Where
- 45 sites in Australia, France and 7 more
- Volunteers
- 208 people
- Sponsor
- Kuros Biosurgery AG
Chronic Hepatitis C
Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)
The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both…
- Trial name
- NCT00446134
- Testing
- Taribavirin, Ribavirin
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Bausch Health Americas, Inc.
Pancreatic Ductal Adenocarcinoma
A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy
This study is open to adults with advanced pancreatic cancer for whom previous treatment was not successful or no treatment exists.
- Trial name
- NCT06528093
- Testing
- BI 765883, Gemcitabine, Nab-paclitaxel
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Peanut Allergy
Oral Immunotherapy for Peanut Allergic Patients
Multicenter, double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral immunotherapy in peanut-allergic patients.
- Trial name
- NCT04163562
- Testing
- INP20
- Where
- 2 sites in Spain
- Volunteers
- 50 people
- Sponsor
- InnoUp Farma S.L.
Pre-frail Elderly, Frail Elderly
Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3
The purpose of this study is to assess the dose of Hy.D Calcifediol 25 SD/S (a metabolite of vitamin D3) which will achieve the range of mean serum 25(OH)D between 75-100nmol/L in physically frail elderly people after 24 weeks of…
- Trial name
- D-DOSE (NCT01868945)
- Testing
- 5 µg/day Hy.D Calcifediol, 10 µg/day Hy.D Calcifediol, 15 µg/day Hy.D Calcifediol
- Where
- Netherlands
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Neoplasms
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
This study is open to adults with different types of advanced cancer (solid tumours). This study is open to people in whom previous treatments were not successful.
- Trial name
- NCT03604445
- Testing
- BI 905677
- Where
- 5 sites in United States, Japan and 2 more
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Prader-Willi Syndrome
Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome
This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.
- Trial name
- PWS (NCT05198362)
- Testing
- Tesomet
- Where
- United States
- Sponsor
- Saniona
Infection, Human Immunodeficiency Virus
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.
- Trial name
- NCT02415595
- Testing
- BMS-955176, EFV, TDF/FTC
- Where
- 64 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- ViiV Healthcare
Myelodysplastic Syndromes
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)
This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.
- Trial name
- NCT00750334
- Testing
- clofarabine
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Genzyme, a Sanofi Company
Lung Cancer, Breast Cancer
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
- Trial name
- NCT06618287
- Testing
- BMS-986507, Osimertinib, Pembrolizumab
- Where
- 65 sites in United States, Australia and 8 more
- Volunteers
- 416 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer, Bladder Cancer
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
The purpose of this trial is to assess the ability of CVA21, either alone (Part A) or in combination with pembrolizumab (Part B), to reach and to replicate in existing tumors (while sparing normal cells) and to establish a safe…
- Trial name
- STORM (NCT02043665)
- Testing
- CVA21/pembrolizumab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 85 people
- Sponsor
- Viralytics
Nasal Congestion Due to Allergic Rhinitis
Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study
The researchers in this study want to find out whether participants with a history of stuffy nose due to allergic reactions in the nose would intend to buy drug Phenylephrine Hydrochloride (Phenylephrine HCl) extended release…
- Trial name
- NCT04534452
- Testing
- Phenylephrine HCl (Sinus Comfort, BAY112476)
- Where
- United States
- Volunteers
- 347 people
- Sponsor
- Bayer
Chronic Abnormal Immune Activation in HIV/AIDS
Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients
This is a multicenter, randomized, double-blind, dose-finding, placebo-controlled study in patients with chronic HIV infection and inadequate immune restoration treated with long-term highly active antiretroviral therapy (HAART).
- Trial name
- NCT04084444
- Testing
- T8 tablet 0.5mg, T8 tablet 1mg
- Where
- 9 sites in China
- Volunteers
- 151 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Pancreatic Neoplasms
Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Determination of the maximum tolerated dose (MTD), safety, and tolerability when BI 2536 was given on Day 1 and Day 15 in combination with gemcitabine given on Day 1, Day 8 and Day 15 every 28 days in patients with locally…
- Trial name
- NCT02215044
- Testing
- BI 2536, intravenous, Gemcitabine, intravenous
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Fibrosing Interstitial Lung Disease
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary…
- Trial name
- NCT07366034
- Testing
- Nerandomilast
- Where
- 47 sites in United States, Argentina and 20 more
- Volunteers
- 35 people
- Sponsor
- Boehringer Ingelheim
Pancreatic Cancer
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer
The purpose of this study is to determine the safety and tolerability of different doses of CP-675,206 in combination with gemcitabine and to determine the maximum dose of CP-675,206 that is well tolerated when given in…
- Trial name
- NCT00556023
- Testing
- CP-675,206 and gemcitabine
- Where
- 5 sites in Canada, Italy
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Multiple Myeloma
SST0001 (Roneparstat) in Advanced Multiple Myeloma
Heparanase cleaves heparan sulfate (HS) chains, a natural substrate for heparanase, and participates in degradation and remodelling of the extra-cellular matrix (ECM) facilitating, among other activities, cell invasion associated…
- Trial name
- NCT01764880
- Testing
- SST0001 (Roneparstat)
- Where
- 5 sites in Germany, Israel and 1 more
- Volunteers
- 19 people
- Sponsor
- Sigma Tau Research Switzerland SA
Anemia, Non-dialysis Dependent Chronic Kidney Disease
Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of orally administered vadadustat in Japanese…
- Trial name
- NCT03054337
- Testing
- Vadadustat
- Where
- 18 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Akebia Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.